Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Patient volumes for GLP-1s more than tripled between Q1 2020 and Q3 2022, yet only 57.0% of these patients had an official type 2 diabetes diagnosis
The SURMOUNT-4 trial data shows that stopping tirzepatide entirely leads to significant weight regain, so maintaining some level of medication support, even at reduced doses, appears to produce better long-term outcomes than complete cessation
All treatment groups had similar improvements in glucose and insulin levels
Even if, in the first couple years of Mounjaro and Wegovy both being approved for the weight loss indication, the impact from just those taking it who can afford it/have the insurance for it can be significant
doi:10.1016/j.exger.2017.08.017
Some people may start to see improvements in blood sugar levels or weight loss within a few weeks of starting treatment, while for others, it may take longer
